← Eichor
Study identifier: NCT07232758 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety, Tolerability and Pharmacokinetic Studies of HRS-2183 for Injection in Healthy Chinese Subjects After Single and Multiple Administration

Condition: Chinese Healthy Adult Subjects  ·  Sponsor: Jiangsu HengRui Medicine Co., Ltd.

PhasePhase 1
Planned participants42
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYes

About this study

This study mainly evaluated the safety and tolerability, as well as the pharmacokinetic characteristics, of the injectable drug HRS-2183 after single and multiple administrations in healthy subjects.

This description comes directly from the study's public registry record.

Talk to the study team

Yuanyuan Huang  ·  +0518-82342973  ·  yuanyuan.huang@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Qilu Hospital of Shandong UniversityJinan, Shandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07232758